title: [The growth inhibition effect of alpha-adrenoceptor antagonists on androgen- independent prostate cancer cell line].
abstract: OBJECTIVE
  The aim of the present study is to compare the effects of two alpha1-adrenoceptor antagonist terazosin and alfuzosin together with one alpha-adrenoceptor antagonist phenoxybenzamine on androgen-independent prostate cancer cell lines PC-3 and DU145.
  
  
  METHODS
  Two androgen- independent cell lines, PC-3 and DU145, were used to determine the cell viability, colony-forming ability as well as cell cycle characteristics after exposure to these three drugs.
  
  
  RESULTS
  This study showed that terazosin inhibited not only prostate cancer cell growth but also colony-forming ability, which is the main target of clinical treatment. On the other hand, alfuzosin and phenoxybenzamine have no effect on cell viability and colony forming ability of PC-3 and DU145. In addition, the terazosin inhibits cell growth through G(1) phase cell cycle arrest.
  
  
  CONCLUSIONS
  This study provided the evidence that alpha1-adrenoceptor antagonist terazosin may have a therapeutic potential in the treatment of advanced androgen-independent prostate cancer.
authors.affiliation: Department of Urology, People's Hospital of Peking University, Beijing 100044, China.
authors.forename: Shi-jun
authors.initials: SJ
authors.lastname: Liu
authors.forename: Ke-xin
authors.initials: KX
authors.lastname: Xu
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Wang
authors.forename: Shu-kun
authors.initials: SK
authors.lastname: Hou
authors.forename: Yun-chuan
authors.initials: YC
authors.lastname: Wang
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D010643:Phenoxybenzamine / Q000494:pharmacology; D011224:Prazosin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000473:pathology*; D011799:Quinazolines / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D000970:Antineoplastic Agents; D011799:Quinazolines; D010643:Phenoxybenzamine; C041226:Terazosin; C047638:alfuzosin; D011224:Prazosin